| Gene symbol | CD5 | Synonyms | LEU1, T1 | Type of gene | protein-coding |
| Chromosome | 11 | Map location | 11q12.2 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | CD5 molecule | ||||
| GTO ID | GTC1703 |
| Trial ID | NCT03081910 |
| Disease | Non-Hodgkin's Lymphoma | T Cell Lymphoblastic Lymphoma | T-Cell Acute Lymphoblastic Leukemia |
| Altered gene | CD5 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CD5 CAR-T cells |
| Generation | 2nd |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen |
| Year | 2017 |
| Country | United States |
| Company sponsor | Baylor College of Medicine |
| Other ID(s) | H-40466, MAGENTA |
| Vector information | |||||
|
|||||
| Cohort1: Autologous cells | |||||||||||||||
|
|||||||||||||||
| Cohort2: Allogeneic cells | |||||||||||||||
|
|||||||||||||||